<DOC>
	<DOC>NCT01533220</DOC>
	<brief_summary>The common cold is a major cause of nasal obstruction and reaches children and adults twice or more times a year. At the moment, there is no cure for the common cold, and therefore the reduction of symptoms is the focus of treatment. The study was designed to parallel distribution, with two equal groups, with one group will receive treatment with a combination of naphazoline hydrocloride + pheniramine maleate + panthenol and the other will receive treatment with naphazoline hydrocloride.</brief_summary>
	<brief_title>Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal</brief_title>
	<detailed_description>STUDY DESIGN - randomized,double blind, prospective,monocentric, parallel group, intent to treat trial - Experiment duration: 5 days - 4 visits (days 0,1,3 and 5) - Evaluation of symptoms reduction - Adverse events evaluation</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Respiration Disorders</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Naphazoline</mesh_term>
	<mesh_term>Pheniramine</mesh_term>
	<mesh_term>Pantothenic Acid</mesh_term>
	<criteria>1. Patients must be able to understand the study procedures, agree to participate and give written consent. 2. Patients aged over 12 years of both sexes; 3. Patients with clinical signs of flu and colds or other upper respiratory allergies; 4. Patients with early signs and symptoms with time of evolution not more than 48 hours; 5. Patients with good mental health; 6. Negative urine pregnancy test 1. Patients treated with antibiotics 2. Current treatment with immunosuppressants (eg.cyclosporine or methotrexate); 3. Use of intranasal cromalin the week before inclusion; 4. Use of decongestants or antihistaminic (intranasal or systemic); 5. Presence of any disease or anatomical abnormality that may difficult the data analysis ; 6. Uncontrolled hypertension; 7. Presence of respiratory symptoms for more than 14 days; 8. History of abuse of drugs and alcohol; 9. Presence of other concomitant pulmonary diseases; 10. Hypersensitivity to any compound of investigational product</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>nasal and nasopharyngeal congestion</keyword>
</DOC>